| Forward-Looking Statement
2
To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts,
assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding
NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,”
“will,” “potential,” “expects,” “believes,” “intends,” “hope,” “towards,” “forward,” “later” and similar expressions. Examples of forward-looking
statements in this presentation include, among others, statements about the development plans for our products, statements about the
progress and evaluation and expected timing of results of NextCure’s ongoing or planned clinical trials, expectations regarding the potential
benefits, activity, effectiveness and safety of our research stage, preclinical stage, and clinical stage therapeutic candidates, NextCure’s
financial guidance, expected upcoming milestones, and NextCure’s plans, objectives and intentions with respect to the discovery and
development of therapeutic products. Forward-looking statements involve substantial risks and uncertainties that could cause actual results
to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts
of the COVID-19 pandemic on NextCure’s business, including NextCure’s clinical trials, third parties on which NextCure relies and NextCure’s
operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and
no products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need to obtain additional financing; risks
related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of
product candidates based on NextCure’s discovery platform; and dependence on key personnel. More detailed information on these and
additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission
(the “SEC”), including in Item 1A of NextCure’s most recent Form 10-K, subsequent Form 10-Q and elsewhere in the Company’s filings with
the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of
this press release, and NextCure assumes no obligation to update any forward-looking statements, except as required by law, even if
expectations change. |